A better approach to growth factors? Scholar Rock raises $47M on SMA promise
Scholar Rock, a biotech based of out Cambridge, MA, just got a $47 million infusion of cash to develop what the company considers smarter, next-generation growth factor drugs. Their approach involves more targeted tweaking than predecessors in the field, giving patients the upside without some unwanted side effects.
That’s the hope, at least, of Scholar Rock’s president and CEO Nagesh Mahanthappa. He tells me the company is taking on spinal muscular atrophy (SMA) first, a rare neuromuscular disease characterized by a loss of motor neurons and progressive muscle wasting (often leading to early death).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.